Late adverse effects and quality of life in survivors of testicular germ cell tumour
Abstract Currently,~ 95% of patients with testicular germ cell tumour (TGCT) are cured,
resulting in an increasing number of TGCT survivors. Although cured, these men face …
resulting in an increasing number of TGCT survivors. Although cured, these men face …
Advances in diagnosis and treatment of testicular cancer
M Chovanec, L Cheng - bmj, 2022 - bmj.com
Testicular cancer is a curable cancer. The success of physicians in curing the disease is
underpinned by multidisciplinary advances. Cisplatin-based combination chemotherapy and …
underpinned by multidisciplinary advances. Cisplatin-based combination chemotherapy and …
Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B …
A Hiester, Y Che, A Lusch, O Kuß, G Niegisch, A Lorch… - European Urology, 2023 - Elsevier
Background Primary retroperitoneal lymph node dissection (RPLND) for clinical stage (CS)
IIA/B seminoma without adjuvant treatment is an experimental treatment to avoid …
IIA/B seminoma without adjuvant treatment is an experimental treatment to avoid …
Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort
R Hellesnes, TÅ Myklebust, SD Fosså… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Using complete information regarding testicular cancer (TC) treatment burden,
this study aimed to investigate cause-specific non-TC mortality with impact on previous …
this study aimed to investigate cause-specific non-TC mortality with impact on previous …
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial
A Papachristofilou, J Bedke, S Hayoz… - The Lancet …, 2022 - thelancet.com
Background Standard treatment options for patients with stage IIA or stage IIB seminoma
include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based …
include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based …
Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer
J Lobo, R Leao, AJM Gillis, A van den Berg… - European Urology …, 2021 - Elsevier
Background Optimal management of clinical stage I (CSI) testicular cancer is controversial
due to lack of robust prognostic factors; miRNA-371a-3p holds promise as a biomarker …
due to lack of robust prognostic factors; miRNA-371a-3p holds promise as a biomarker …
Testicular cancer in 2023: Current status and recent progress
DJ McHugh, JP Gleeson… - CA: A Cancer Journal for …, 2024 - Wiley Online Library
Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young
adult men. Progress in the management of GCT has been made in the last 50 years, with a …
adult men. Progress in the management of GCT has been made in the last 50 years, with a …
Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study
MP Myklebust, A Thor, B Rosenlund, P Gjengstø… - Scientific Reports, 2021 - nature.com
Abstract MicroRNA-371a-3p (miR371) has been suggested as a sensitive biomarker in
testicular germ cell cancer (TGCC). We aimed to compare miR371 with the classical …
testicular germ cell cancer (TGCC). We aimed to compare miR371 with the classical …
[HTML][HTML] Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between …
DJ van der Meer, WTA van der Graaf, D van de Wal… - ESMO open, 2024 - Elsevier
Background Few studies have comprehensively investigated the long-term second cancer
risk among adolescent and young adult (AYA, aged 15-39 years) cancer survivors. This …
risk among adolescent and young adult (AYA, aged 15-39 years) cancer survivors. This …
Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: results from the first Italian population‐based cohort
A Trama, A Tittarelli, G Barigelletti, L Botta, G Gatta… - Cancer, 2022 - Wiley Online Library
Background Evidence about late effects in adolescent and young adult (AYA) cancer
survivors is scarce. This study assessed the risk of subsequent malignant neoplasms …
survivors is scarce. This study assessed the risk of subsequent malignant neoplasms …